Associate Professor, Oncologic Sciences, USF-Morsani
Oncology
Dr. Eric B. Haura, MD
|
|
Give Review
Eric Haura is an expert in the field of Oncology. He researched medicine at Duke University School of Medicine. Duke University School of Medicine is a top medical college. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. Eric Haura is also a published doctor. He has 99 publication published. The most recent publication is: Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling. Eric Haura is registered with Medicare and accepts Medicare payments.
Publications
- Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.
- β-Arrestin-1 Mediates Nicotine-Induced Metastasis through E2F1 Target Genes That Modulate Epithelial-Mesenchymal Transition.
- Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.
- Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung Cancer...
- Annotation of human Cancers with EGFR signaling-associated protein complexes using proximity ligation assays.
- Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung Cancer patients.
- Role of LKB1-CRTC1 on Glycosylated COX-2 and Response to COX-2 Inhibition in Lung Cancer.
- Update on third-generation EGFR tyrosine kinase inhibitors.
- Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations.
- Identification of kinase inhibitor targets in the lung Cancer microenvironment by chemical and phosphoproteomics.
- Deploying ibrutinib to lung Cancer: another step in the quest towards drug repurposing.
- Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patien...
- The ethical imperative of risk disclosure in research: the answer is always yes.
- TGF-β-inducible microRNA-183 silences tumor-associated natural killer Cells.
- Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung Cancer.
- Stakeholder perceptions of thoracic rapid tissue donation: An exploratory study.
- Altruism in terminal Cancer patients and rapid tissue donation program: does the theory apply?
- ExtraCellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration.
- GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells.
- Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell-based Vaccine for Refractory Lung Adenocarcinoma.
- Non-canonical IKKs, IKKõ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung Cancer.
- Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung Cancer.
- Healthcare providers' knowledge and attitudes about rapid tissue donation (RTD): phase one of establishing a rapid tissue donation programme in thoracic oncology.
- IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung Cancer.
- A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung AdenoCarcinoma.
- Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer.
- Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
- Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung Cancer.
- An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation.
- A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in Cancer.
- ID1 facilitates the growth and metastasis of non-small cell lung Cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling.
- A phase I study of tasisulam sodium (LY573636 sodium), a novel antiCancer compound in patients with refractory solid tumors.
- Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage ...
- JAK1 activates STAT3 activity in non-small-cell lung Cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
- ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of Lung tumors.
- Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung Cancer cells.
- Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
- Characterizing tyrosine phosphorylation signaling in lung Cancer using SH2 profiling.
- Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung Cancer.
- A pilot study of preoperative gefitinib for early-stage lung Cancer to assess intratumor drug concentration and pathways mediating primary resistance.
- Src inhibitors in lung Cancer: current status and future directions.
- Targeting epidermal growth factor receptor: central signaling kinase in lung Cancer.
- Molecular origins of lung Cancer: prospects for personalized prevention and therapy.
- Relationship between tumor size and survival among patients with resection of multiple synchronous lung Cancers.
- Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling.
- A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung Cancer.
- A chemical and phosphoproteomic characterization of dasatinib action in lung Cancer.
- Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung Cancer.
- Dasatinib in solid Tumors.
- Nicotine promotes tumor growth and metastasis in mouse models of lung Cancer.
- Src kinases as therapeutic targets for Cancer.
- Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung Cancer cells.
- MUC1 is a downstream target of STAT3 and regulates lung Cancer cell survival and invasion.
- Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human Cancer cell lines.
- IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry.
- Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung Cancer.
- Proteomic contributions to personalized Cancer care.
- Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small Cell lu...
- Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung Cancer (NSCLC) who are 70 years of age or older.
- Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung Cancer cells.
- Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung Cancer.
- A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung Cancer cells.
- SRC and STAT pathways.
- Effects of IFN-gamma and Stat1 on gene expression, growth, and survival in non-small cell lung Cancer cells.
- Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small Cell and neuroendo...
- DNA synthesis and repair genes RRM1 and ERCC1 in lung Cancer.
- Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung Cancer cell lines and human lung tumors.
- Nicotine induces Cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways.
- Dasatinib (BMS-354825) selectively induces apoptosis in lung Cancer cells dependent on epidermal growth factor receptor signaling for survival.
- Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung Cancer development and dissemination?
- Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.
- Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung Cancer.
- Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung Cancer.
- Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in Cancer.
- Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
- Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung Cancer.
- Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung Cancer.
- EGR1 predicts PTEN and survival in patients with non-small-cell lung Cancer.
- Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung Cancer cells.
- Stat3 regulates genes common to both wound healing and Cancer.
- Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance.
- Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression p...
- Antiapoptotic signaling pathways in non-small-cell lung Cancer: biology and therapeutic strategies.
- RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung Cancer.
- Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung Cancer: case report and review of literature.
- Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity.
- Efficient down-regulation of cyclin A-associated activity and expression in suspended primary keratinocytes requires p21(Cip1).
- Gefitinib (ZD1839) in previously treated advanced non-small-cell lung Cancer: experience from a single institution.
- Gene therapy for lung Cancer.
- P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes.
- Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small Cell carcinoma Cells.
- Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1.
- Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung Cancer.
- Gene therapy for lung Cancer. An introduction.
- Fulminant hepatic failure due to disseminated adenovirus infection in a patient with chronic lymphocytic leukemia.
- Management of advanced non-small cell lung Cancer: current trends.
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.
- Direct repression of the Mcl-1 promoter by E2F1.
Schools
Duke University School Of Medicine
Johns Hopkins Hospital
Clinical Fellow Duke University Medical CenterHematology amp Oncology
Research Fellow Duke University Medical CenterGenetics
Bs Johns Hopkins UniversityBiomedical Engineering
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Accepts most major Health Plans. Please contact our office for details.
Education
-
Duke University Hospital -
Johns Hopkins University -
Duke University School of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1801829007 | |
| NPPES Provider LastName | HAURA | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 154.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801829007 |
| Last Name Of The Provider | HAURA |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
Dr. Michael V. Jaglal, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Joyson J. Karakunnel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kendra L. Sweet, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jhanelle Gray, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Frederick Locke, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mary C. Pinder-Schenck, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Trinidad Caintic, MD
This Doctor is OpenDoctor Recommended.
|